Oculis Holding AG (NASDAQ:OCS) Receives Consensus Rating of “Moderate Buy” from Analysts

Oculis Holding AG (NASDAQ:OCS) has earned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $41.00.

Several equities analysts have recently issued reports on OCS shares. Needham & Company LLC started coverage on Oculis in a research note on Wednesday, August 27th. They issued a “buy” rating and a $36.00 price objective for the company. Chardan Capital boosted their target price on Oculis from $33.00 to $51.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research note on Wednesday, October 8th. HC Wainwright boosted their target price on Oculis from $33.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, October 7th. Finally, Wall Street Zen cut Oculis from a “hold” rating to a “sell” rating in a research note on Sunday, September 21st.

Institutional Investors Weigh In On Oculis

Several institutional investors have recently added to or reduced their stakes in OCS. Pivotal bioVenture Partners Investment Advisor LLC lifted its stake in Oculis by 32.4% during the first quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company’s stock worth $43,784,000 after purchasing an additional 563,078 shares during the last quarter. SR One Capital Management LP purchased a new stake in Oculis in the first quarter valued at approximately $6,137,000. Aberdeen Group plc lifted its stake in Oculis by 24.1% in the first quarter. Aberdeen Group plc now owns 1,253,119 shares of the company’s stock valued at $23,847,000 after buying an additional 243,695 shares during the last quarter. Alyeska Investment Group L.P. purchased a new stake in Oculis in the first quarter valued at approximately $2,499,000. Finally, Marshall Wace LLP purchased a new stake in Oculis in the second quarter valued at approximately $393,000. Hedge funds and other institutional investors own 22.30% of the company’s stock.

Oculis Stock Performance

Shares of OCS opened at $19.28 on Tuesday. The stock has a 50-day simple moving average of $18.69 and a 200-day simple moving average of $18.54. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.55 and a current ratio of 4.55. The stock has a market capitalization of $841.76 million, a PE ratio of -7.22 and a beta of 0.29. Oculis has a 1 year low of $14.00 and a 1 year high of $23.08.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Thursday, August 21st. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.06). The company had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $0.14 million. Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. On average, analysts predict that Oculis will post -2.09 earnings per share for the current fiscal year.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.